Navigation Links
Antidepressant Tied to Dangerous Heart Rhythm, FDA Says
Date:8/24/2011

WEDNESDAY, Aug. 24 (HealthDay News) -- High doses of the popular antidepressant Celexa can cause potentially fatal abnormal heart rhythms and should no longer be prescribed to patients, the U.S. Food and Drug Administration said Wednesday.

Doses of Celexa (citalopram hydrobromide) greater than 40 milligrams a day can cause changes in the electrical activity of the heart, which can lead to abnormal heart rhythms, including a potentially deadly arrhythmia known as Torsade de Pointes, according to the agency.

Patients at high risk for changes in the electrical activity of the heart include those with pre-existing heart conditions (including congestive heart failure) and those prone to low levels of potassium and magnesium in the blood, the FDA said.

Even though studies have not found that doses higher than 40 mg a day offer any benefits to patients with depression, Celexa's drug labeling previously stated that some patients may require a dose of 60 mg a day, the agency noted.

The label has been revised to include the new dosage limit as well as information about the potential for abnormal heart electrical activity and rhythms.

Celexa belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), which also include widely used medications such as Paxil, Prozac and Zoloft.

More information

The American Academy of Family Physicians has more about antidepressants.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, Aug. 24, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Americans Use of Antidepressants On the Rise: Study
2. Certain Antidepressants Linked to Falls in Nursing Homes
3. Two Antidepressants Given to Dementia Patients Ineffective: Study
4. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
5. UT Southwestern researchers uncover why ketamine produces a fast antidepressant response
6. Common Painkillers May Blunt Antidepressants
7. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
8. U. Iowa study suggests antidepressants aid physical recovery in stroke
9. Study Hints at Link Between Antidepressants and Heart Trouble
10. Antidepressants linked to thicker arteries
11. New model for probing antidepressant actions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antidepressant Tied to Dangerous Heart Rhythm, FDA Says
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: